CRNX News and Press, Crinetics Pharmaceuticals Inc. From 11/08/23

Crinetics Pharmaceuticals Inc. (CRNX) is expected to report $-0.89 for Q3 2023

Phase 3 PATHFNDR-1 Study Met Primary and All Secondary Endpoints as Reported in September Phase 3 PATHFNDR-2 Study Topline Data Expected in 1Q 2024 Initial Data from Phase 2 Study of Paltusotine in Carcinoid Syndrome Expected in December 2023 SAN DIEGO, Nov. 07, 2023 (GLOB...

2023-10-11 09:00:38 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – October 11, 2023 – USA News Group –  Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A re...

2023-10-03 07:00:18 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips As economic and stock market uncertainty looms, you may think at first that now is not a great time to be dabbling in speculative stocks. Yet, while the broad market may be experiencing tur...

SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference, which is being held in New York City on September 26-2...

2023-09-19 09:11:54 ET From Sept. 10 to Sept. 15, Crinetics Pharmaceuticals (NASDAQ: CRNX) stock price gained 83%, and it's still climbing rapidly. The pre-revenue biotech's lead candidate, called paltusotine, reported some great phase 3 results, suggesting that the once-daily oral ...

2023-09-18 12:15:50 ET Summary San Diego-based biotech Crinetics Pharmaceuticals saw its share price soar by 75% after positive results from its Phase 3 study of paltusotine, an oral treatment for acromegaly. The study met its primary endpoint and all secondary endpoints, with 83%...

2023-09-15 08:37:48 ET Shares of the rare disease specialist Crinetics Pharmaceuticals (NASDAQ: CRNX) have been on fire this week. Through the first four days of trading, the biotech's stock has already gained a healthy 81.3%, according to data provided by S&P Global Market In...

2023-09-13 06:45:06 ET More on Crinetics Pharmaceuticals Seeking Alpha’s Quant Rating on Crinetics Pharmaceuticals Crinetics Pharmaceuticals: Creating Next-Generation Treatments In Acromegaly Crinetics Pharmaceuticals: Paltusotine Phase 3 Data Presented At END...

SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing ...